Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date And Expects Adcom Meeting In Late July

Loading news article.

Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date And Expects Adcom Meeting In Late July | WAPE

Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date And Expects Adcom Meeting In Late July

Article summary

Related companies

Comments —